AI assistant
Sending…
GALECTIN THERAPEUTICS INC — Director's Dealing 2018
May 24, 2018
33422_dirs_2018-05-24_1e1478b1-a9e1-4eb1-9484-c212ca74e373.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2018-05-22
Reporting Person: CALLICUTT JACK W (Chief Financial Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-05-22 | Stock option (right to buy) | $4.16 | A | 90000 | Acquired | 2028-05-22 | Common Stock (90000) | Direct |
Footnotes
F1: The options vest as follows: 25% on June 30, 2018, 25% on September30, 2018, and 50% on December 31, 2018.
More from GALECTIN THERAPEUTICS INC
Earnings Release
2026
May 15
Interim / Quarterly Report
2026
May 15
Capital/Financing Update
2026
Mar 31
Earnings Release
2026
Mar 31
Annual Report
2026
Mar 31
Director's Dealing
2026
Mar 17
Director's Dealing
2026
Mar 17
Board/Management Information
2026
Mar 17
Director's Dealing
2026
Feb 9
Board/Management Information
2026
Jan 21